DTIL PRECISION BIOSCIENCES INC
Price Chart
Executive Summary
Precision BioSciences held its 2026 annual meeting on May 21, 2026, with roughly 86% of shares represented. Shareholders narrowly approved a 3,800,000-share increase to the 2019 Incentive Award Plan (11.2M for, 8.1M against), elected directors Melinda Brown and Geno Germano, ratified Deloitte & Touche as auditor, approved say-on-pay, and adopted an officer exculpation amendment to the certificate of incorporation. The filing is an administrative post-meeting report with no financial performance data; the equity plan expansion enables future equity grants but also represents potential dilution.
Actionable Insight
The narrowly approved equity plan expansion (57.8% For) and officer exculpation amendment are governance items with no immediate earnings impact. Monitor future 10-Q filings for actual equity grant activity under the expanded plan, as the 3.8M-share reserve is material relative to current share count (~14.6% potential dilution). No stock-moving catalysts in this filing.
Key Facts
- Annual meeting held May 21, 2026; 22,304,867 shares (86% of outstanding) were represented.
- Shareholders approved a 3,800,000-share increase to the 2019 Incentive Award Plan with 11,170,635 votes For, 8,145,992 Against — a relatively narrow margin of 57.8% For.
- Melinda Brown (14,348,888 For) and Geno Germano (14,288,270 For) were elected as Class I directors to serve until the 2029 annual meeting.
- Deloitte & Touche LLP was ratified as independent auditor for FY2026 with 22,198,597 For.
- Advisory say-on-pay was approved (18,696,193 For, 612,836 Against).
- Stockholders approved an amendment to the certificate of incorporation (17,909,703 For) to provide officer exculpation as permitted under Delaware law, filed with the Secretary of State on May 22, 2026.
- No departures of directors or officers were reported; no CEO/CFO changes occurred.
Financial Impact
No financial data in this filing. The equity plan increase adds up to 3,800,000 new common shares available for issuance, representing approximately 14.6% dilution relative to the roughly 26M shares outstanding (based on 86% representation of 22.3M shares implying ~25.9M total outstanding on record date). Actual dilutive impact depends on future grant activity.
Risk Factors
- Potential future dilution from grants under the expanded equity plan (~3.8M new shares authorized).
- Relatively high 'Against' vote on equity plan (42.2% Against) signals some institutional dissatisfaction with dilution; could foreshadow future proxy challenges.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-038220 |
| Document: dtil-20260521.htm | 0001628280-26-038220 |
| Document: dtil-proposedamendmenttoar.htm | 0001628280-26-038220 |
| Document: 0001628280-26-038220-index-headers.html | 0001628280-26-038220 |
| Document: 0001628280-26-038220-index.html | 0001628280-26-038220 |
| Document: 0001628280-26-038220.txt | 0001628280-26-038220 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
17d ago
|
8-K
| $7.59 $6.32 | ▼ −16.73% | ▼ −17.94% | $6.10 (−19.63%) |
|
May 26, 2026
17d ago
|
8-K
| $7.59 $6.04 | ▼ −20.42% | ▼ −20.89% | $6.10 (−19.63%) |
|
May 5, 2026
5w ago
|
8-K
| $7.45 $8.20 | ▲ +10.07% | ▲ +8.08% | $6.10 (−18.12%) |
|
Apr 8, 2026
9w ago
|
DEFA14A
| $5.99 $7.66 | ▲ +27.88% | ▲ +24.36% | $6.10 (+1.84%) |
|
Mar 12, 2026
13w ago
|
8-K
| $5.67 $6.72 | ▲ +18.52% | ▲ +19.50% | $6.10 (+7.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access